ASND Assumed by UBS -- Price Target Lowered to $269

gurufocus.com · 2026-10-15

Ascendis Pharma (ASND) Receives Buy Rating from UBS On October 3, 2023, UBS assumed coverage of Ascendis Pharma (ASND) with a rating of Buy. The firm has adj

Read the full story at gurufocus.com →